ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!2seventy bio, Inc. (TSVT) stock declined over -6.99%, trading at $2.66 on NASDAQ, down from the previous close of $2.86. The stock opened at $2.86, fluctuating between $2.65 and $2.82 in the recent session.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Employees | 274 |
Beta | 1.74 |
Sales or Revenue | $100.39M |
5Y Sales Change% | -0.131% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com